BACKGROUND: Patients with high-risk HR+/HER2- early breast cancer remain at high-risk of recurrence despite adjuvant endocrine therapy. The monarchE trial demonstrated that the addition of abemaciclib for two years significantly improves invasive disease-free survival (IDFS) and overall survival (OS) in patients with node-positive, high-risk patients. However, the prolonged treatment duration and the toxicity profile of abemaciclib make treatment tolerability and dose modifications particularly relevant in clinical practice. METHODS: This single center, retrospective study included 254 consecutive patients with high-risk, HR+/HER2- early breast cancer, who initiated adjuvant abemaciclib between March 2022 and May 2026. Clinicopathological characteristics, treatment related adverse events, dose modifications and discontinuations were collected. Clinicopathological characteristics and treatment outcomes following recurrence were also evaluated. Univariable and multivariable logistic regression analyses were performed. IDFS, DRFS and PFS were estimated using Kaplan-Meier method. RESULTS: Median age at abemaciclib initiation was 55.5 years; median follow-up was 23.3 months. At least one AE occurred in 99.6% of patients, mostly low grade. The most frequent AE was diarrhea, occurred in 89.8% of patients, followed by neutropenia (64.6%) and fatigue (57.5%). Grade 3 diarrhea and neutropenia occurred in 2.4% and 14.6% of patients, respectively. Dose reductions were required in 169 patients (66.5%), while 55 (21.7%) discontinued abemaciclib before the planned 2 years. Early discontinuation for any reason was significantly more frequent among patients aged 70 years than among younger patients (39.2% vs 17.2%, p<0.001). Increasing age (p= 0.042) and ECOG 1 (p=0.037) were independently associated with toxicity-related discontinuation. Sixteen patients (6.3%) developed breast cancer recurrence, including 15 distant relapses. Estimated 24-months IDFS and DRFS were 92.1% and 94.3%, 3 respectively. Among 12 patients with paired tumor samples, 7 (58.3%) showed loss of ER expression at recurrence. Median PFS after the first-line treatment was 5.9 months (95% CI 2.5-10.8). CONCLUSIONS: This real-world study supports the feasibility of adjuvant abemaciclib in high-risk HR+/HER2- early breast cancer. Although AEs and dose reductions were common, discontinuation due to toxicity occurred in a minority of patients. Older age and ECOG PS 1 were associated with discontinuation, highlighting the importance of toxicity management. The frequent ER loss at recurrence supports reassessment of tumor biology to guide subsequent treatment.

BACKGROUND: Patients with high-risk HR+/HER2- early breast cancer remain at high-risk of recurrence despite adjuvant endocrine therapy. The monarchE trial demonstrated that the addition of abemaciclib for two years significantly improves invasive disease-free survival (IDFS) and overall survival (OS) in patients with node-positive, high-risk patients. However, the prolonged treatment duration and the toxicity profile of abemaciclib make treatment tolerability and dose modifications particularly relevant in clinical practice. METHODS: This single center, retrospective study included 254 consecutive patients with high-risk, HR+/HER2- early breast cancer, who initiated adjuvant abemaciclib between March 2022 and May 2026. Clinicopathological characteristics, treatment related adverse events, dose modifications and discontinuations were collected. Clinicopathological characteristics and treatment outcomes following recurrence were also evaluated. Univariable and multivariable logistic regression analyses were performed. IDFS, DRFS and PFS were estimated using Kaplan-Meier method. RESULTS: Median age at abemaciclib initiation was 55.5 years; median follow-up was 23.3 months. At least one AE occurred in 99.6% of patients, mostly low grade. The most frequent AE was diarrhea, occurred in 89.8% of patients, followed by neutropenia (64.6%) and fatigue (57.5%). Grade 3 diarrhea and neutropenia occurred in 2.4% and 14.6% of patients, respectively. Dose reductions were required in 169 patients (66.5%), while 55 (21.7%) discontinued abemaciclib before the planned 2 years. Early discontinuation for any reason was significantly more frequent among patients aged 70 years than among younger patients (39.2% vs 17.2%, p<0.001). Increasing age (p= 0.042) and ECOG 1 (p=0.037) were independently associated with toxicity-related discontinuation. Sixteen patients (6.3%) developed breast cancer recurrence, including 15 distant relapses. Estimated 24-months IDFS and DRFS were 92.1% and 94.3%, 3 respectively. Among 12 patients with paired tumor samples, 7 (58.3%) showed loss of ER expression at recurrence. Median PFS after the first-line treatment was 5.9 months (95% CI 2.5-10.8). CONCLUSIONS: This real-world study supports the feasibility of adjuvant abemaciclib in high-risk HR+/HER2- early breast cancer. Although AEs and dose reductions were common, discontinuation due to toxicity occurred in a minority of patients. Older age and ECOG PS 1 were associated with discontinuation, highlighting the importance of toxicity management. The frequent ER loss at recurrence supports reassessment of tumor biology to guide subsequent treatment.

A retrospective, real-world experience with adjuvant abemaciclib in high-risk HR+/HER2− early breast cancer: tolerability, dose modifications, and outcomes.

NAPETTI, DAVIDE
2024/2025

Abstract

BACKGROUND: Patients with high-risk HR+/HER2- early breast cancer remain at high-risk of recurrence despite adjuvant endocrine therapy. The monarchE trial demonstrated that the addition of abemaciclib for two years significantly improves invasive disease-free survival (IDFS) and overall survival (OS) in patients with node-positive, high-risk patients. However, the prolonged treatment duration and the toxicity profile of abemaciclib make treatment tolerability and dose modifications particularly relevant in clinical practice. METHODS: This single center, retrospective study included 254 consecutive patients with high-risk, HR+/HER2- early breast cancer, who initiated adjuvant abemaciclib between March 2022 and May 2026. Clinicopathological characteristics, treatment related adverse events, dose modifications and discontinuations were collected. Clinicopathological characteristics and treatment outcomes following recurrence were also evaluated. Univariable and multivariable logistic regression analyses were performed. IDFS, DRFS and PFS were estimated using Kaplan-Meier method. RESULTS: Median age at abemaciclib initiation was 55.5 years; median follow-up was 23.3 months. At least one AE occurred in 99.6% of patients, mostly low grade. The most frequent AE was diarrhea, occurred in 89.8% of patients, followed by neutropenia (64.6%) and fatigue (57.5%). Grade 3 diarrhea and neutropenia occurred in 2.4% and 14.6% of patients, respectively. Dose reductions were required in 169 patients (66.5%), while 55 (21.7%) discontinued abemaciclib before the planned 2 years. Early discontinuation for any reason was significantly more frequent among patients aged 70 years than among younger patients (39.2% vs 17.2%, p<0.001). Increasing age (p= 0.042) and ECOG 1 (p=0.037) were independently associated with toxicity-related discontinuation. Sixteen patients (6.3%) developed breast cancer recurrence, including 15 distant relapses. Estimated 24-months IDFS and DRFS were 92.1% and 94.3%, 3 respectively. Among 12 patients with paired tumor samples, 7 (58.3%) showed loss of ER expression at recurrence. Median PFS after the first-line treatment was 5.9 months (95% CI 2.5-10.8). CONCLUSIONS: This real-world study supports the feasibility of adjuvant abemaciclib in high-risk HR+/HER2- early breast cancer. Although AEs and dose reductions were common, discontinuation due to toxicity occurred in a minority of patients. Older age and ECOG PS 1 were associated with discontinuation, highlighting the importance of toxicity management. The frequent ER loss at recurrence supports reassessment of tumor biology to guide subsequent treatment.
2024
A retrospective, real-world experience with adjuvant abemaciclib in high-risk HR+/HER2− early breast cancer: tolerability, dose modifications, and outcomes.
BACKGROUND: Patients with high-risk HR+/HER2- early breast cancer remain at high-risk of recurrence despite adjuvant endocrine therapy. The monarchE trial demonstrated that the addition of abemaciclib for two years significantly improves invasive disease-free survival (IDFS) and overall survival (OS) in patients with node-positive, high-risk patients. However, the prolonged treatment duration and the toxicity profile of abemaciclib make treatment tolerability and dose modifications particularly relevant in clinical practice. METHODS: This single center, retrospective study included 254 consecutive patients with high-risk, HR+/HER2- early breast cancer, who initiated adjuvant abemaciclib between March 2022 and May 2026. Clinicopathological characteristics, treatment related adverse events, dose modifications and discontinuations were collected. Clinicopathological characteristics and treatment outcomes following recurrence were also evaluated. Univariable and multivariable logistic regression analyses were performed. IDFS, DRFS and PFS were estimated using Kaplan-Meier method. RESULTS: Median age at abemaciclib initiation was 55.5 years; median follow-up was 23.3 months. At least one AE occurred in 99.6% of patients, mostly low grade. The most frequent AE was diarrhea, occurred in 89.8% of patients, followed by neutropenia (64.6%) and fatigue (57.5%). Grade 3 diarrhea and neutropenia occurred in 2.4% and 14.6% of patients, respectively. Dose reductions were required in 169 patients (66.5%), while 55 (21.7%) discontinued abemaciclib before the planned 2 years. Early discontinuation for any reason was significantly more frequent among patients aged 70 years than among younger patients (39.2% vs 17.2%, p<0.001). Increasing age (p= 0.042) and ECOG 1 (p=0.037) were independently associated with toxicity-related discontinuation. Sixteen patients (6.3%) developed breast cancer recurrence, including 15 distant relapses. Estimated 24-months IDFS and DRFS were 92.1% and 94.3%, 3 respectively. Among 12 patients with paired tumor samples, 7 (58.3%) showed loss of ER expression at recurrence. Median PFS after the first-line treatment was 5.9 months (95% CI 2.5-10.8). CONCLUSIONS: This real-world study supports the feasibility of adjuvant abemaciclib in high-risk HR+/HER2- early breast cancer. Although AEs and dose reductions were common, discontinuation due to toxicity occurred in a minority of patients. Older age and ECOG PS 1 were associated with discontinuation, highlighting the importance of toxicity management. The frequent ER loss at recurrence supports reassessment of tumor biology to guide subsequent treatment.
early breast cancer
abemaciclib
real-world
File in questo prodotto:
File Dimensione Formato  
Napetti_Davide.pdf

Accesso riservato

Dimensione 1.33 MB
Formato Adobe PDF
1.33 MB Adobe PDF

The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12608/119674